Indivior (INVVY) Stock Price, News & Analysis

Company Overview

Indivior PLC is a specialty pharmaceutical company focused on developing and commercializing treatments for addiction and related disorders. The company’s core business centers on addressing opioid use disorder through a portfolio of branded pharmaceuticals and delivery systems designed to support long-term recovery. Indivior’s therapies are aimed at improving patient outcomes by reducing withdrawal symptoms and lowering the risk of relapse.

The company’s flagship product, Suboxone®, is a buprenorphine-naloxone sublingual film approved for the treatment of opioid dependence. In addition to Suboxone, Indivior markets Sublocade®, an extended-release buprenorphine injection, and offers generic formulations of medication-assisted therapies. Its ongoing research and development efforts encompass next-generation formulations and novel compounds intended to enhance safety, efficacy and patient adherence.

Indivior was established in July 2014 following a spin-off from Reckitt Benckiser Group PLC, with its corporate headquarters in Slough, United Kingdom, and its U.S. headquarters in Richmond, Virginia. Since its inception, the company has expanded its commercial reach to serve patients and healthcare providers across North America, Europe, Australia and select markets in Asia. Indivior maintains manufacturing and distribution capabilities in multiple geographies to support global supply chains.

The leadership team is led by Chief Executive Officer Mark Crossley, who brings extensive experience in specialty pharmaceuticals and global operations. Under his direction, Indivior continues to invest in clinical programs and strategic partnerships aimed at advancing its pipeline. The company’s management emphasizes a patient-centric approach, collaborating with governments, payers and advocacy groups to improve access to evidence-based addiction treatments worldwide.

Key Stats

• Today's Range: $21.64 to $21.85
• 50-Day Range: $21.85 to $21.85
• 52-Week Range: $14.76 to $35.50
• Volume: 8,100 shs
• Average Volume: 3,825 shs
• Market Capitalization: $3.01 billion
• P/E Ratio: 20.81
• Dividend Yield: N/A
• Price Target: $50.00
• Consensus Rating: Buy

Indivior Stock Analysis - MarketRank™

Indivior scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Indivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Indivior has a consensus price target of $50.00, representing about 128.9% upside from its current price of $21.85.

Amount of Analyst Coverage

Indivior has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 46.77%

Earnings Growth

Earnings for Indivior are expected to grow by 46.77% in the coming year, from $1.24 to $1.82 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Indivior is 20.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of Indivior is 20.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.04.

Price to Book Value per Share Ratio

Indivior has a P/B Ratio of 15.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for INVVY.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Indivior does not currently pay a dividend.

Dividend Growth

Indivior does not have a long track record of dividend growth.

News and Social Media

• Score: 0.4 / 5
• News Sentiment: -1.42

News Sentiment

Indivior has a news sentiment score of -1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Indivior this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Indivior insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.05% of the stock of Indivior is held by institutions.

INVVY Stock Analysis - Frequently Asked Questions

How have INVVY shares performed this year?

Indivior's stock was trading at $21.8455 at the beginning of the year. Since then, INVVY stock has increased by 0.0% and is now trading at $21.8455.

How do I buy shares of Indivior?

Shares of INVVY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:INVVY
• Previous Symbol: NASDAQ:INVVY
• CIK: 1625297
• Web: www.indivior.com
• Phone: 804-379-1090
• Fax: 804-379-1215
• Employees: 800
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Indivior: $50.00
• High Price Target: $50.00
• Low Price Target: $50.00
• Potential Upside/Downside: +128.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 20.81
• Forward P/E Ratio: 17.62
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $791 million
• Price / Sales: 3.81
• Cash Flow: $1.15 per share
• Price / Cash Flow: 18.94
• Book Value: $1.45 per share
• Price / Book: 15.07

Miscellaneous

• Outstanding Shares: 137,880,000
• Free Float: N/A
• Market Cap: $3.01 billion
• Optionable: Not Optionable
• Beta: 0.35